CytoDyn Announces FDA Approval Of Patient Screening For Phase 2b Study With Lead Product Candidate PRO 140 For The Treatment Of HIV Type 1
Published: Jan 08, 2014
VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1 (HIV-1). The Phase 2b study is being conducted by Drexel University College of Medicine and funded by grants from the National Institutes of Health (NIH).
Help employers find you! Check out all the jobs and post your resume.